



Press Release

FOR IMMEDIATE RELEASE

CRITICAL OUTCOME TECHNOLOGIES INC. APPOINTS CHIEF OPERATING OFFICER AND ISSUES STOCK OPTIONS

London, Ontario (May 11, 2007): Critical Outcome Technologies Inc. (TSX Venture: COT), announced today that Mr. Scott Baker has been appointed Chief Operating Officer of Critical Outcome Technologies Inc. (COTI). Under his employment agreement dated May 10, 2007 and pursuant to the Stock Option Plan approved by the Board, the Corporation granted 100,000 stock options to Mr. Baker. The exercise price is \$1.34 per share and vesting occurs over 3.25 years based upon contract milestones with the first 25,000 options vesting on October 1, 2007.

In this newly-created role, Mr. Baker will lead COTI's business operations and external stakeholder relationships. "I am delighted to welcome Scott to the COTI team. During his 25 year career, Scott has consistently built organizations' capacity, efficiency and profitability by way of strategic leadership, innovative operational excellence and consistent focus on financial results. His most recent experience in managing pharmaceutical companies will be a major factor in the development and growth of COTI," said John Drake, Chairman and Chief Executive Officer of COTI.

Mr. Baker's career in business management began while attending the University of Western Ontario, where he operated a successful franchise, concurrent with achieving an economics & accounting degree. Following graduation in 1984, he joined Procter & Gamble Inc. leading to increasingly senior management roles. From 1989 to 1999, Mr. Baker was engaged in a series of successive senior leadership roles with several Tier 1 multi-national consumer products companies including Tambrands Canada Inc., Everfresh Canada Inc. and Quaker Canada Beverages. In 1999 he was appointed Vice President, Sales of Novartis Consumer Health, a prominent global pharmaceutical & OTC manufacturer. Prior to joining COTI, Mr. Baker was appointed President and Chief Operating Officer of a privately-held Canadian-owned pharmaceutical manufacturer. Under his direction, this organization achieved rapid & sustained growth by acquisition, strategic alliances, international business development and market penetration of core drug therapies to clinical and pharmacy healthcare practitioners.

"I have tremendous confidence in CHEMSAS® and the COTI Team. I strongly believe that our mission to accelerate and optimize the drug discovery process can dramatically improve human health." said Scott Baker, Chief Operating Officer. "I look forward to identifying areas to leverage the Company's proprietary technology to achieve growth and sustained profitability."

About Critical Outcome Technologies Inc. (COTI)

COTI is formed around a unique computational platform technology called CHEMSAS®, which allows for the accelerated identification, profiling and optimization of targeted small molecules potentially effective in the treatment of human diseases for which current therapy is either lacking or ineffective. COTI's business is focused on the discovery and pre-clinical development of libraries of novel, optimized lead molecules for the



Press Release

treatment of specific cancers, HIV and multiple sclerosis. Currently, five targeted libraries of lead compounds (small cell lung cancer, multiple sclerosis, HIV integrase inhibitors, colorectal cancer, and acute myelogenous leukemia in adults) are under active development.

For further information, visit the website at www.criticaloutcome.com or contact:

Michael Barr
Director of Business Development and Marketing
519-858-5157
mbarr@criticaloutcome.com

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.